Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04494295 · ClinicalTrials.gov registry record
The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation
A clinical trial of Supratentorial Hemorrhage, sponsored by Integra LifeSciences Corporation.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT04494295: Recruiting study of Supratentorial Hemorrhage, sponsored by Integra LifeSciences Corporation.
NCT04494295 is a study of Supratentorial Hemorrhage that is actively recruiting participants, run by Integra LifeSciences Corporation. The registered enrollment target is 500 participants. The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04494295, a study of Supratentorial Hemorrhage, is actively recruiting participants, sponsored by Integra LifeSciences Corporation.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.
Primary Outcome
Rate of surgical success defined as reduction to \< 15 cc total volume of the supratentorial intracerebral hemorrhage on immediate Post-op CT Scan
Conditions Studied
Interventions
- DEVICE Aurora Surgiscope System
Study Locations (20)
Florida
- University of Miami - Miami
- University of South Florida - Tampa
Missouri
- University of Missouri - Columbia
- Washington University in St. Louis - St Louis
New York
- University at Buffalo - Buffalo
- Icahn School of Medicine at Mount Sinai - New York
Pennsylvania
- Pennsylvania State University - Hershey
- University of Pennsylvania - Philadelphia
California
- Providence Health - Burbank
Illinois
- Rush University Medical Center - Chicago
Maryland
- MedStar Health Research Institute - Baltimore
Michigan
- Corewell Health - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2029-10-15 |
What NCT04494295 shows while recruiting
NCT04494295 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Supratentorial Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Aurora Surgiscope System is the first listed.
NCT04494295 names 20 study sites across 16 states, led by Florida, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT04494295 about?
NCT04494295 is a clinical study titled "The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation". This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery ...
What is the current status of trial NCT04494295?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2020-10-23. Estimated completion is 2029-10-15.
What conditions does trial NCT04494295 study?
This clinical trial studies the following conditions: Supratentorial Hemorrhage.
What interventions are being tested in trial NCT04494295?
The interventions under investigation include: Aurora Surgiscope System (DEVICE).
Who is sponsoring clinical trial NCT04494295?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04494295 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI